Health
New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis
ZUG, Switzerland, December 17, 2025--Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements observed as early as 48 hours after treatment in some patients with atopic dermatitis and prurigo nodularis.1 The findings from post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs were published in the Journal of the European Academy of Derma
About this update from Galderma Group Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":823,"height":209,"url":"https://media.zenfs.com/en/business-wire.com/5fb95a9de6ca7888cca6263902ca93c2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/27NBoDMM1W4kvDaUDs3S1g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5fb95a9de6ca7888cca6263902ca93c2","width":823,"height":209},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Z6vnMTSs6iUx95d63A3M7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2NDY7aD00MTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5fb95a9de6ca7888cca6263902ca93c2","width":823,"height":209}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab’s fast onset of action and improvement of itch and sleep disturbance in patients with moderate-to-severe atopic dermatitis and prurigo nodularis1","length":328,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Significant improvements in itch were observed as early as 48 hours after initial treatment and steadily increased through to Day 141","length":133,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Nemolizumab is the first approved monoclonal antibody that specifically targets and inhibits the signalling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in atopic dermatitis and prurigo nodularis2-4","length":223,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Nemolizumab is approved by multiple regulatory authorities around the world for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis, including in the U.S. and EU5,6","length":188,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":872,"olType":false},{"type":"text","content":"ZUG, Switzerland, December 17, 2025--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements observed as early as 48 hours after treatment in some patients with atopic dermatitis and prurigo nodul...